Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utilizing feline oral squamous cell carcinoma patients to develop NQO1-targeted therapy.

Neoplasia (New York, N.Y.) - 1 Aug 2021

Lundberg Alycen P, Boudreau Matthew W, Selting Kim A, Chatkewitz Lindsay E, Samuelson Jonathan, Francis Joshua M, Parkinson Elizabeth I, Barger Anne M, Hergenrother Paul J, Fan Timothy M

Abstract excerpt

Developing effective therapies for the treatment of advanced head-and-neck squamous cell carcinoma (HNSCC) remains a major challenge, and there is a limited landscape of effective targeted therapies on the horizon. NAD(P)H:quinone oxidoreductase 1 (NQO1) is a 2-electron reductase that is overexpressed in HNSCC and presents as a promising target for the treatment of HNSCC. Current NQO1-targeted drugs are hindered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cats
Share to Combined Modality Therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Management

Share to Drug Evaluation, Preclinical

Share to Molecular Targeted Therapy

Share to Mouth Neoplasms

Share to NAD(P)H Dehydrogenase (Quinone)

Share to Tomography, X-Ray Computed

Source

Open in PubMed Open full text

Identifiers

PMID: 34246985
DOI: 10.1016/j.neo.2021.06.008
PMCID: PMC8274297

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utilizing feline oral squamous cell carcinoma patients to develop NQO1-targeted therapy.PMID 34246985Read ↗

Treatment of Fanconi Anemia–Associated Head and Neck Cancer: Opportunities to Improve OutcomesSemantic proximity Read ↗

APR-246 & COTI-2 increase chemoradiotherapy sensitivity via ROS-induced DNA damage and ferroptosis in p53 mutant HPV negative head and neck squamous cell carcinomaSemantic proximity Read ↗

Bioactivation of Napabucasin Triggers Reactive Oxygen Species–Mediated Cancer Cell DeathSemantic proximity Read ↗

Single cell kinetic modeling of redox-based drug metabolism in head and neck squamous cell carcinomaSemantic proximity Read ↗

Senataxin modulates resistance to cisplatin through an R-loop mediated mechanism in HPV-associated Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

Cisplatin-induced genetic alterations in KEAP1 promote therapeutic resistance in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Molecular characterization of AIFM2/FSP1 inhibition by iFSP1-like moleculesSemantic proximity Read ↗

FIS103, a Novel SULT1A1-dependent Prodrug, Demonstrates Potent Antitumor Activity in Renal Cell CarcinomaSemantic proximity Read ↗

Inhibition of the ubiquitin-proteasome system by a bioactivatable compoundSemantic proximity Read ↗

Adaphostin-Induced Oxidative Stress in Oesophageal Neuroendocrine Carcinoma: A Potential Therapeutic StrategySemantic proximity Read ↗

The superoxide dismutase mimetic GC4419 enhances tumor killing when combined with stereotactic ablative radiationSemantic proximity Read ↗

Multi-Center “Replica Study” Challenges the Impact of Electronic Cigarette Aerosols on Cisplatin Resistance in Head and Neck Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.